| Bioactivity | Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging[1]. |
| CAS | 257943-19-4 |
| Sequence | {Hynic}-{d-Phe}-Cys-Tyr-{d-Trp}-Lys-Thr-Cys-{Thr-ol} (Disulfidebridge:Cys2-Cys7) |
| Shortening | {Hynic}-{d-Phe}-CY-{d-Trp}-KTC-{Thr-ol} (Disulfidebridge:Cys2-Cys7) |
| Formula | C55H71N13O12S2 |
| Molar Mass | 1170.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Decristoforo C, et al. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000 Sep;27(9):1318-25. |
Hynic-toc
CAS: 257943-19-4 F: C55H71N13O12S2 W: 1170.36
Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.